Vlastnictví managementu společnosti Suda Pharmaceuticals Ltd
Jaká je hodnota metriky Vlastnictví managementu společnosti Suda Pharmaceuticals Ltd?
Hodnota metriky Vlastnictví managementu společnosti Suda Pharmaceuticals Ltd je 13.19%
Jaká je definice metriky Vlastnictví managementu?
Vlastnictví managementu (Insider Ownership) je poměr akcií vlastněných akcionáři v rámci firmy (akcionáři, kteří vlastní více než 5% společnosti nebo ve funkci ředitele či vedoucího odddělení) a veškerých vydaných akcií.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Vlastnictví managementu společností v sektoru Health Care sektor na ASX ve srovnání se společností Suda Pharmaceuticals Ltd
Čemu se věnuje společnost Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Firmy s metrikou vlastnictví managementu podobnou společnosti Suda Pharmaceuticals Ltd
- Hodnota metriky Vlastnictví managementu společnosti Braille Systems je 13.15%
- Hodnota metriky Vlastnictví managementu společnosti Mesoblast je 13.16%
- Hodnota metriky Vlastnictví managementu společnosti Ipsos SA je 13.16%
- Hodnota metriky Vlastnictví managementu společnosti Creative Media & Community Trust je 13.16%
- Hodnota metriky Vlastnictví managementu společnosti Aurion Resources je 13.18%
- Hodnota metriky Vlastnictví managementu společnosti Touchstone Exploration je 13.18%
- Hodnota metriky Vlastnictví managementu společnosti Suda Pharmaceuticals Ltd je 13.19%
- Hodnota metriky Vlastnictví managementu společnosti ANI Pharmaceuticals Inc je 13.20%
- Hodnota metriky Vlastnictví managementu společnosti BNP Paribas SA je 13.20%
- Hodnota metriky Vlastnictví managementu společnosti Scorpio Tankers Inc je 13.20%
- Hodnota metriky Vlastnictví managementu společnosti Lundin Mining je 13.20%
- Hodnota metriky Vlastnictví managementu společnosti St George Mining je 13.21%
- Hodnota metriky Vlastnictví managementu společnosti Alerus je 13.21%